Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Our experienced team of physicians and researchers have dedicated their lives to finding cures for children just like yours — children who suffer from the more common solid tumors such as Wilms tumor, neuroblastoma, and sarcomas as well as the more rare solid cancers such as retinoblastoma, melanoma and adrenocortical carcinoma.
Survival Rates: Our team of experts has helped increase the survival rates of various solid tumors, including:
Retinoblastoma: St. Jude has one of the largest groups dedicated to the treatment of the rare and highly curable eye tumor retinoblastoma. Our team of experts includes oncologists, radiation treatment specialists, pathologists, laboratory investigators and ophthalmologists (eye specialists). This group was the first to publish a detailed genetic analysis of retinoblastoma. Our laboratory research has identified genetic changes in the tumor that may be used to develop new treatments for this disease.
Rare Cancers: Our team includes experts in the treatment of rare but devastating childhood cancers such as melanoma, adrenocortical carcinoma and nasopharyngeal carcinoma. In children with melanoma, our team pioneered the use of pegylated interferon. This slow-release medication does not have to be given as often and helps the child’s immune system destroy the tumor. We also helped develop a nationwide treatment trial for adrenocortical carcinoma. With support from basic scientists, we are uncovering the genetic hallmarks of both adrenocortical carcinoma and melanoma. This could lead to earlier detection and new strategies for treatment of these diseases.
Bone Tumors: Our Solid Tumor Team leads a team of experts in orthopedic surgery, radiology, pathology, physical therapy and oncology. This group has helped introduce new drugs to treat osteosarcoma. We have pioneered new imaging techniques that evaluate the response of tumors to treatment and detect where the disease may have spread. We have also incorporated surgical techniques that prevent the need for amputation and encourage growth of the affected limb.
Drug Discovery: St. Jude has played a prominent leadership role in identifying potential new active drugs such as Irinotecan, topotecan and temsirolimus, which are now used to treat children with rhabdomyosarcoma, retinoblastoma and neuroblastoma.
Soft-tissue Sarcomas: The St. Jude Solid Tumor Team has identified key features of soft-tissue sarcomas that help predict which patients are at risk for their disease to return or spread to other parts of their body. These findings led to the development of a national study that will define which patients may benefit from additional treatments after surgery, such as chemotherapy or radiation therapy.
Improved Antibodies: Our experts have been instrumental in developing an antibody (which helps the child’s immune system identify and neutralize foreign objects) against certain tumors such as neuroblastoma. This treatment may have fewer side effects than other antibodies currently being used.
Bilateral Wilms Tumor: Our surgeons have extensive experience and surgical ability to preserve as much normal kidney as possible on both sides for children with this cancer.
Surgical Expertise: Our surgeons are increasing the use of cutting-edge, minimally invasive surgery (laparoscopy and thoroscopy). The benefits of these treatments include smaller scars, less pain and quicker post-operative recovery.
Click the links on the left to read more about our treatment program, treatment team, and why St. Jude is the best place for your child’s solid tumor treatment.
To find out about enrolling your child in one of our clinical studies, have your physician call:
or (901) 595-4055
or fax relevant information to
We are available to help you 24 hours a day, seven days a week.